Immunotherapy plus chemoradiation for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new immunotherapy drug (enlansibumab) given together with standard chemoradiation for locally advanced cervical cancer. It aims to see if adding this drug helps shrink tumors and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman between 18 and 70 years old.
- Your cervical cancer must be a specific type (squamous cell, adenocarcinoma, or adenosquamous) and at stage IIB to IVA (locally advanced).
- You cannot have had any prior treatment for cervical cancer (no surgery, chemo, or radiation).
- You cannot have active autoimmune disease or uncontrolled infections.
- You must be willing to provide a tumor tissue sample for testing PD-L1 and other markers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
This trial tests giving the immunotherapy drug ivonescimab with chemotherapy before standard chemoradiation in women with high-risk, locally advanced cervical cancer that has not spread to distant organs. The goal is to see if this combination can improve treatment outcomes.
This trial tests a new drug called Enlonstobart, which helps the immune system fight cancer, given with standard chemotherapy and radiation for patients with locally advanced cervical cancer. The goal is to see if this combination is effective and safe.
This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
Hear when a new LOCALLY ADVANCED CERVICAL CANCERS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.